Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine if metformin administered in combination
with chemotherapy to women with advanced ovarian, primary peritoneal or fallopian tube cancer
will improve recurrence-free survival at 18 months compared to controls.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center